Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus Disease 2019 (COVID-19). No effective therapy currently exist for prevention or treatment.
Inhaled and intranasal ciclesonide are approved by Health Canada for the treatment of asthma and allergic rhinitis (hay fever). There is some evidence that ciclesonide may be helpful to reduce the symptoms of COVID-19 but more information is needed to determine if this drug should be used routinely or not.
We hypothesize that ciclesonide is superior to placebo at reducing the symptoms of COVID-19 disease, specifically shortness of breath. We hypothesize it may helpful in preventing progression of symptoms among those with mild COVID-19 disease.
This study is part of a national randomized clinical trial led by Dr. Nicole Ezer at the Research Institute of the McGill University Health Centre and Dr. Sara Belga at the University of British Columbia, that aims at assessing if inhaled and intranasal ciclesonide is effective at reducing the symptoms of COVID-19 disease.
We are recruiting adults in BC who have symptoms of COVID-19 (fever, cough OR shortness of breath) and confirmed lab diagnosis of COVID-19 within 5 days of enrolment.
Participants will be randomized to receive either inhaled and intranasal Ciclesonide or placebo (inhalers and nasal sprays that look like study medication but contain no active ingredients).
The participation in this internet-based clinical trial will last 14 days for non-hospitalized participants, and 29 days for hospitalized participants. It will include at least 7 virtual visits (email responses and online questionnaires). Each visit/questionnaire should take about 10 minutes to complete.